SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
暂无分享,去创建一个
G. Mills | E. Winer | K. Do | F. Meric-Bernstam | A. Sahin | R. Kurzrock | A. González-Angulo | S. Piha-Paul | L. Doyle | Shuying Liu | Yisheng Li | A. Akcakanat | Huiqin Chen | Vivianne Velez-Bravo | I. Krop | S. Moulder-Thompson | E. Tarco | K. Culotta
[1] G. Mills,et al. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] A. Tolcher,et al. Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors , 2014, Journal of Hematology & Oncology.
[3] S. Chandarlapaty,et al. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors , 2013, Breast Cancer Research.
[4] Anandita Rajpurohit,et al. PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System , 2013, Clinical Cancer Research.
[5] G. Mills,et al. Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer , 2012, Clinical Cancer Research.
[6] G. Hortobagyi,et al. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer , 2012, Cancer.
[7] David Olmos,et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Majumder,et al. MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.
[9] A. Tolcher,et al. Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors , 2010, Clinical Cancer Research.
[10] H. Kunikane,et al. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI. , 2009, Japanese journal of clinical oncology.
[11] Yiling Lu,et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.
[12] G. Mills,et al. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. , 2009, Cancer research.
[13] Funda Meric-Bernstam,et al. Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Zhi Hu,et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.
[15] G. Mills,et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.
[16] G. Wilding,et al. Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.
[17] Yiling Lu,et al. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.
[18] Hanina Hibshoosh,et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.
[19] D. Crivellari,et al. Long-Term, weekly One-Hour Infusion of Paclitaxel in Patients with Metastatic Breast Cancer: A Phase II Monoinstitutional Study , 2004, Tumori.
[20] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[21] Tsuyoshi Saito,et al. Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). , 2003, Japanese journal of clinical oncology.
[22] M. Tonato,et al. Weekly Paclitaxel in Metastatic Breast Cancer Patients: A Phase II Study , 2002, Tumori.
[23] E. Perez,et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[25] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[26] C. Hudis,et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .